Orthobiologics Market

Orthobiologics Market Size:

The global orthobiologics market size reached US$ 6.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.1 Billion by 2032, exhibiting a growth rate (CAGR) of 4.5% during 2024-2032. The rising demand for minimally invasive surgeries (MIS), ongoing advancements in biologic treatments, growing geriatric populations, increasing incidences of musculoskeletal disorders, improved healthcare infrastructure, escalating cases of sports injuries, and ongoing technological innovations in bone grafts, stem cell therapy, and regenerative medicine are some of the key factors contributing to the market expansion.

Orthobiologics Market Analysis:

• Major Market Drivers: The increasing demand for minimally invasive (MI) procedures is fueling growth in the orthobiologics market, as these treatments offer effective solutions with reduced recovery times and lower surgical risks. In line with this, significant advancements in regenerative medicine, including stem cell and platelet-rich plasma therapies, are impelling the market expansion by providing innovative treatments for musculoskeletal injuries and degenerative conditions.
• Key Market Trends: The surging popularity of viscosupplementation products due to their effectiveness in managing osteoarthritis symptoms by improving joint lubrication and reducing pain is strengthening the market growth. In line with this, knee joints’ high susceptibility to degenerative conditions and injuries is further contributing to the increasing demand for orthobiologics. Moreover, the high prevalence of osteoarthritis and degenerative arthritis is boosting the orthobiologics market value.
• Geographical Trends: North America leads the market due to its high prevalence of musculoskeletal disorders, advanced healthcare infrastructure, and significant investments in research and development (R&D) by major companies. Along with this, the expanding penetration of hospitals and ambulatory centers in North America and other regions offering comprehensive diagnostic and treatment capabilities are also fueling the demand for orthobiologic therapies.
• Competitive Landscape: Some of the major market players in the orthobiologics industry include Arthrex Inc, Globus Medical Inc., Integra LifeSciences, Johnson & Johnson, Medline Industries Inc., Medtronic plc, NuVasive Inc, Orthofix Medical Inc., Smith & Nephew plc, Stryker Corporation, Terumo Corporation, Wright Medical Group N.V. Zimmer Biomet, among many others.
• Challenges and Opportunities: High costs of orthobiologic treatments and regulatory hurdles can limit market growth and accessibility, particularly in developing regions. On the other hand, ongoing advancements in technology and research offer opportunities for the development of new and improved orthobiologic products while increasing awareness and preference for non-surgical treatments are creating growth prospects in emerging markets.
   

Orthobiologics Market Trends:

Increasing demand for minimally invasive procedures

Orthobiologics have gained significant attention due to their ability to enhance healing, particularly in minimal invasive surgeries (MIS). With advancements in technologies such as image-guided systems and arthroscopy, MISs are becoming more popular for treating musculoskeletal injuries. Orthobiologics, which include bone graft substitutes, viscosupplements, and stem cell therapies, are increasingly being used in these procedures due to their regenerative properties, which help reduce recovery time and improve patient outcomes. Consequently, the trend toward less invasive procedures that offer reduced hospital stays and complications that can effectively promote tissue regeneration without significant trauma, is supporting the orthobiologics market growth.

Advances in regenerative medicine

The orthobiologics market is also experiencing growth from significant innovations in regenerative medicine, particularly in stem cell therapy and platelet-rich plasma (PRP) therapy. Regenerative medicine focuses on repairing or regenerating damaged tissues and organs, and orthobiologics play a critical role in this domain. Stem cells, which can differentiate into various cell types, are being used to treat joint diseases, cartilage defects, and ligament injuries. The ongoing R&D of novel products, including growth factors and matrix proteins that promote bone and tissue healing, are contributing to the expanding applications of orthobiologics in orthopedic and sports medicine. Besides this, PRP therapy, which involves using the patient’s own blood components to improve healing, is becoming widely adopted in treating chronic injuries, which is also impacting the orthobiologics market outlook.

Aging population

The rising elderly population is a major factor contributing to the demand for orthobiologic products. As individuals age, they are more likely to suffer from degenerative musculoskeletal disorders such as osteoarthritis and osteoporosis, which require therapeutic intervention. Orthobiologic treatments provide useful ways to manage these conditions by promoting tissue regeneration and bone healing.  Orthopedic conditions such as joint pain and fractures are common in the elderly population, and biological treatments are a better option than more invasive surgical methods for treating these conditions. As a result, the increasing prevalence of age-related bone disorders and the preference for treatments that minimize recovery time, pain, and postoperative complications have led to a surge in orthobiologics demand for managing age-related musculoskeletal problems.

Orthobiologics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global orthobiologics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, type, application and end user.

Breakup by Product:

• Demineralized Bone Matrix
• Allograft
• Bone Morphogenetic Protein
• Viscosupplementation Products
• Synthetic Bone Substitutes
• Others
   

Viscosupplementation products account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product. This includes demineralized bone matrix, allograft, bone morphogenetic protein, viscosupplementation products, synthetic bone substitutes, and others. According to the report, viscosupplementation products represented the largest segment.

On the basis of the orthobiologics market research report, viscosupplementation products dominate the market owing to their effectiveness in treating osteoarthritis, particularly of the knee. These substances, which are mostly made of hyaluronic acid, are injected into joints to cushion and lubricate them, thereby minimizing discomfort and enhancing range of motion. As osteoarthritis is highly prevalent, especially in the aging population, the demand for non-surgical and minimally invasive treatment options like viscosupplementation is high. Moreover, viscosupplements offer relief without the significant risks or recovery time associated with joint replacement surgery. Therefore, the ease of administration, growing preference for non-invasive treatments, and increasing awareness of viscosupplementation’s benefits contribute to the increasing orthobiologics demand.

Breakup by Type:

• Knee
• Ankle
• Hip
• Wrist and Shoulder
• Spine
• Others
   

Knee holds the largest share of the industry

A detailed breakup and analysis of the market based on the type have also been provided in the report. This includes knee, ankle, hip, wrist and shoulder, spine, and others. According to the report, knee accounted for the largest market share.

The high incidence of degenerative conditions in knees like osteoarthritis and injuries such as ligament tears and cartilage damage is acting as another crucial factor driving the demand for orthobiologics. The knee joint, being a weight-bearing joint, is particularly susceptible to wear and tear over time, leading to significant pain and reduced mobility. Orthobiologic treatments, including viscosupplementation and regenerative therapies, are frequently used to alleviate symptoms and improve function in knee conditions. The high prevalence of knee disorders among both the aging population and athletes, combined with the effectiveness of orthobiologic interventions in reducing pain and promoting healing, is bolstering the market demand.

Breakup by Application:

• Osteoarthritis and Degenerative Arthritis
• Spinal Fusion
• Fracture Recovery
• Soft Tissue Injuries
• Maxillofacial and Dental Applications
   

Osteoarthritis and degenerative arthritis represent the leading market segment 

The report has provided a detailed breakup and analysis of the market based on the application. This includes osteoarthritis and degenerative arthritis, spinal fusion, fracture recovery, soft tissue injuries, and maxillofacial and dental applications. According to the report, osteoarthritis and degenerative arthritis represented the largest segment.

As per the orthobiologics market overview, osteoarthritis and degenerative arthritis are the leading market segments due to their widespread prevalence and impact. These conditions are characterized by the progressive breakdown of joint cartilage, leading to pain, stiffness, and impaired function, particularly in weight-bearing joints like the knees and hips. As the global population ages and more individuals experience these age-related joint issues, the demand for effective treatments grows. Orthobiologic solutions, such as viscosupplementation and regenerative therapies, offer non-surgical options to manage symptoms, improve mobility, and enhance quality of life. Their ability to address the root causes of joint degeneration, combined with a growing preference for MISs is bolstering the orthobiologics market revenue.

Breakup by End User:

• Hospitals and Ambulatory Centers
• Research and Academic Institutes
• Dental Clinics and Facilities
• Orthopedic Clinics
   

Hospitals and ambulatory centers exhibit a clear dominance in the market 

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals and ambulatory centers, research and academic institutes, dental clinics and facilities, and orthopedic clinics. According to the report, hospitals and ambulatory centers accounted for the largest market share.

Hospitals and ambulatory centers are the biggest end user segment due to their comprehensive diagnostic and treatment capabilities. These facilities are equipped with advanced imaging and surgical technologies that enable precise administration of orthobiologic treatments, such as injections and regenerative therapies. Hospitals and ambulatory centers often offer a range of specialized services, including orthopedic surgery and rehabilitation, which integrate seamlessly with ortho-biologic interventions. Furthermore, the ability to manage complex cases and provide immediate medical support enhances the appeal of these settings for both patients and providers. The concentration of skilled healthcare professionals and access to cutting-edge treatments in these facilities are further contributing to the demand for orthobiologics in these settings.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America leads the market, accounting for the largest orthobiologics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for orthobiologics.

The orthobiologics market forecast shows that North America leads the market with its high prevalence of musculoskeletal disorders, such as osteoarthritis, expanding geriatric population, and widespread trends of engaging in high levels of physical activity and sports. Advanced healthcare infrastructure and a high standard of medical care in the U.S. and Canada support the adoption of innovative orthobiologic treatments. Moreover, North America is home to major pharmaceutical and biotech companies that invest heavily in R&D, driving the availability of cutting-edge products. The region’s strong regulatory framework and significant healthcare spending further facilitate market growth, making it a leader in the adoption and utilization of orthobiologics.

Competitive Landscape:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the orthobiologics industry include Arthrex Inc, Globus Medical Inc., Integra LifeSciences, Johnson & Johnson, Medline Industries Inc., Medtronic plc, NuVasive Inc, Orthofix Medical Inc., Smith & Nephew plc, Stryker Corporation, Terumo Corporation, Wright Medical Group N.V., Zimmer Biomet, etc.
  
  (Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
   
• The competitive landscape is marked by a dynamic interplay between major pharmaceutical companies, specialized biotech firms, and emerging players. Leading companies with a broad portfolio of products and extensive distribution networks are investing heavily in R&D to innovate and enhance their offerings, particularly in areas like viscosupplementation and regenerative therapies. At the same time, smaller biotech firms are driving competition through specialized, cutting-edge solutions and novel technologies, such as stem cell therapies and advanced growth factors. Additionally, the market is characterized by strategic alliances and mergers among orthobiologics companies, which enhance market reach and capabilities. Besides this, regulatory approvals and clinical advancements significantly influence market dynamics, making the industry highly competitive and continuously evolving.

Orthobiologics Market News:

• In May 2024, AKVA Surgical partnered with BONESUPPORT™ to introduce the CERAMENT® portfolio in Australia. BONESUPPORT, known for its innovative injectable bioceramic bone graft substitutes, offers products like CERAMENT® BONE VOID FILLER and CERAMENT® G, which use the proprietary CERAMENT® technology to promote bone remodeling and drug elution. These solutions provide clinical benefits in treating trauma, chronic osteomyelitis, diabetic foot osteomyelitis, and revision arthroplasty.
• In April 2024, Xtant Medical Holdings, Inc. announced the full commercial launch of its amniotic membrane allografts, SimpliGraft™ and SimpliMax™, designed for chronic and acute wound protection. These dehydrated, irradiated amniotic membrane sheets provide a barrier against environmental factors.
• In September 2023, Berkeley Biologics, a GNI Group subsidiary, will acquire Elutia’s orthobiologics business unit for up to $35 million. The deal includes a $15 million upfront payment and up to $20 million in potential earnout payments over five years. Elutia is also working towards FDA clearance for its drug-eluting product, CanGaroo, which provides extended antibiotic protection for cardiac devices.

Orthobiologics Market Report Scope:

Key Questions Answered in This Report:

• How has the global orthobiologics market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global orthobiologics market?
• What is the impact of each driver, restraint, and opportunity on the global orthobiologics market?
• What are the key regional markets?
• Which countries represent the most attractive orthobiologics market?
• What is the breakup of the market based on the product?
• Which is the most attractive product in the orthobiologics market?
• What is the breakup of the market based on the type?
• Which is the most attractive type in the orthobiologics market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the orthobiologics market?
• What is the breakup of the market based on the end user?
• Which is the most attractive end user in the orthobiologics market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global orthobiologics market?

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the orthobiologics market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global orthobiologics market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the orthobiologics industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.